Mankind Pharma Ltdhas informed BSE that the meeting of the Board of Directors of the Company is scheduled on 03/02/2026 ,inter alia, to consider and approve approval of unaudited standalone ....
MANKIND · price
▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.
Awaiting price reaction for this filing.
Mankind Pharma has informed the exchanges that its Board of Directors will meet on Tuesday, February 3, 2026, to consider and approve the unaudited standalone and consolidated financial results for the quarter and nine months ended December 31, 2025 (Q3FY26 / 9MFY26). The filing is a routine regulatory disclosure under SEBI Listing Regulations. The trading window for dealing in the company's shares will remain closed till February 5, 2026, as per insider trading rules.
No direct impact on the stock from this notice itself — it is a standard advance intimation. Investors should watch the February 3 results announcement for actual revenue, profit, and margin trends in the pharmaceutical business.